Skip to main content
OpenTrials
Completed

NCT Number: NCT07216274

Quantitative Transmission Imaging Compared With MRI as Supplemental Screening for High Lifetime Risk of Breast Cancer

This clinical trial compares the use of quantitative transmission imaging (QTI) to standard of care MRI as a supplemental screening tool for patients with a high lifetime risk of breast cancer. QTI is a single 3D ultrasound test intended to be used as an initial evaluation method for asymptomatic women identified with above-average risk for developing breast cancer. Using QTI may be an effective supplemental screening tool, compared to MRI for patients with a high lifetime risk of breast cancer.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Mayo Clinic in Rochester

Rochester, Minnesota, 55905, United States

About this study

In this prospective feasibility study, 25-30 women over the age of 18 years of age with a high lifetime risk of breast cancer >20% (as calculated by a risk assessment model such as Tyrer-Cuzick) and scheduled for a clinically ordered contrast-enhanced breast MRI were included. Exclusion criteria included pregnant or lactating patients, patients with open breast wounds or nipple discharge, patients heavier than 350 pounds, patients unable to lie prone for more than 15 minutes, and patients with a bra size larger than DDD. Enrolled patients were scheduled for a QT examination within 30 days of their clinical MRI. No additional follow-up appointments were required after the QTI exam.

Images from both imaging modalities were reviewed in consensus by four breast radiologists with 2-24 years of experience. Each interpretation was read without the benefit of prior history. The radiologists knew only that the breast MRI was a clinically indicated high-risk screening breast MRI. Since it was possible that one of the radiologists may have interpreted a breast MRI in the study, recall bias was mitigated by waiting about two months before interpreting the cases. The QTI scans were read in a randomized order. Later that same day, the MRI scans were read in randomized order. Up to three findings per breast could be reported for each imaging modality. For each finding, imaging characteristics, size, and location were recorded. A Breast Imaging Reporting and Data System (BI-RADS) score was assigned for each finding.

Weighted Cohen's kappa evaluated agreement between MRI and QTI BI-RADS scores. Unweighted Cohen's kappa used after dichotomizing scores into negative (BI-RADS 1-2) vs positive (BI-RADS 3-5) categories.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Women 18+ years of age
  • High lifetime risk of breast cancer as determined by a risk assessment tool such a Tyrer-Cuzick model
  • Clinical ordered screening MRI.
  • MRI and QTI performed within 30 days of each other
  • Breasts that will fit in the quantitate transmission (QT) Ultrasound Breast Scanner (e.g. bra cup size less than DDD)

Exclusion criteria

  • Pregnant patients
  • Lactating patients
  • Patients with open wounds or discharge
  • Patients < 18 years of age
  • Patients who are > 350 lbs
  • Patients who are unable to lay prone for >15 minutes

Treatment and study plan

QT Ultrasound Breast Scanner

Device

Undergo Quantitative Transmission Imaging (QTI) using the QT Ultrasound Breast Scanner

Other names: 3D ultrasound, QTI, QT Ultrasound, Quantitative Transmission Ultrasound (QTUS), Quantitative Transmission Imaging

Questionnaire Administration

Other

Ancillary studies

Primary outcomes

  1. Number of Findings for the Total MRI Interpretations and Total QTI Interpretations Performed

    Time frame: Baseline

    Assessed by the number of positive findings. For each finding, imaging characteristics, size, and location were recorded. A Breast Imaging Reporting and Data System (BI-RADS) score was assigned for each finding. If biopsies are obtained, then findings will be compared to histopathologic diagnosis.

Sponsors and collaborators

Lead sponsor

Mayo Clinic

Other

Registry information

Official study title

Quantitative Transmission Imaging Evaluation (QTIE Study) Compared With MRI as Supplemental Screening in Patients With High Lifetime Risk of Breast Cancer

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Oct 14, 2025
Registry last updated
Aug 20, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.